Event Details
Agenda
Abstracts
Event Details
Meeting Summary (PDF, 535.64 KB)
Meeting Objectives
Benign prostatic hyperplasia (BPH) affects 50% of men over age 50. Ninety percent of men over age 80 become affected. Often men with BPH present with lower urinary tract symptoms (LUTS) and first-line treatment of such symptoms include medical management with 5a-reductase inhibitors to reduce prostate size and a -blockers to relax the urinary sphincter. Surgical therapies to resect the prostate can also be effective. However, many men do not find symptom relief from these prostate-targeted treatments and prostate size is often not correlated with severity of urinary symptoms. This raises the question as to whether male LUTS and BPH are syndromic or whether we should re-examine male LUTS within the framework of separating prostate pathology from bladder pathology. Over the last several years, new insights have emerged regarding the etiology of BPH, as well as the etiology of bladder dysfunction. There have also been significant advances in our understanding of the biology of aging, primarily from model systems. Given these advances, it is an opportune time to incorporate these data into a new understanding of BPH etiology and how prostate pathology relates to male LUTS.
Registration Deadline
April 1, 2022
Agenda
Wednesday, March 30, 2022
- 11:00 a.m. – 11:30 a.m.
- Opening Remarks and Objectives
- 11:30 a.m. – 1:00 p.m.
- Session 1: Landscape: Relationship between Benign Prostatic Hyperplasia (BPH) and Male Lower Urinary Tract Symptoms (LUTS)
- Overview
Claus Roehrborn, M.D., The University of Texas Southwestern Medical Center
- Epidemiology of BPH/LUTs—What Have We Learned from Current Cohorts?
Marvin Langston, Ph.D., Kaiser Permanente
- LUTS Clinical Workup and Approach to Treatment
Brian Helfand, M.D., Ph.D., University of Chicago
- 1:00 p.m. – 1:15 p.m.
- Break
- 1:15 a.m. – 2:15 p.m.
- Session 2: Prostate Biology and Pathobiology
- Prostate Development
Chad Vezina, Ph.D., University of Wisconsin
- Human Prostate Cellular Anatomy and Relationship to BPH Pathology
Doug Strand, Ph.D., The University of Texas Southwestern Medical Center
- 2:15 p.m. – 2:30 p.m.
- Session Change
- 2:30 p.m. – 3:30 p.m.
- Breakout Sessions: Identifying Roadblocks and Priorities
- Group 1: Molecular/Cellular/Physiological Mechanisms of BPH and LUTS; Development of a Conceptual Model/Approach to Molecular Endophenotypes
- Group 2: Translational Approaches; Identifying New Therapeutic Targets
- Group 3: Needed Methods and Tools
- Group 4: Clinical Research Needs and Approaches (Includes Health Services and EPI and Health Disparities)
- 3:30 p.m. – 4:00 p.m.
- Initial Reports Back From Breakout Sessions
- 4:00 p.m.
- Day 1 Recess
Thursday, March 31, 2022
- 11:00 a.m. – 11:15 a.m.
- Recap of Day 1 and Plans for Day 2
- 11:15 a.m. – 12:15 p.m.
- Trainee Short Talks/Poster Session
- 12:15 p.m. – 2:00 p.m.
- Session 3: Pathways to Pathology
- Aging
Teresa Liu, Ph.D., University of Wisconsin
- Immune Dysfunction
Travis Jerde, Ph.D., Indiana University School of Medicine
- Androgen Signaling Pathways
Aria Olumi, M.D., Beth Israel Deaconess Medical Center
- Fibrosis and LUTS
William Ricke, Ph.D., University of Wisconsin
- 2:00 p.m. – 2:30 p.m.
- Break
- 2:30 p.m. – 3:30 p.m.
- Session 4: Relationship between Pathology and Symptoms
- Role of Bladder–prostate Crosstalk—Neural Manifestations
Janet Keast, Ph.D., University of Melbourne
- Pathways forward to Understanding Bladder Dysfunction Post-BPH/Adaptations of Bladder
Ramy Goueli, M.D., University of Texas Southwestern Medical Center
- 3:30 p.m.
- Day 2 Recess
Friday, April 1, 2022
- 11:00 a.m. – 11:15 a.m.
- Recap of Day 2 and Plans for Day 3
- 11:15 a.m. – 12:45 p.m.
- Session 5: Approaches, Technologies, Data Sources, and Tools
- High-throughput Interrogations
James Brooks, M.D., Stanford University
- Novel Imaging Approaches
Peter Caravan, Ph.D., Massachusetts General Hospital
- Utilizing Electronic Health Record (EHR) Data to Understand Disease
Tina Hernandez-Boussard, Ph.D., Stanford University
- 12:45 p.m. – 1:00 p.m.
- Break
- 1:00 p.m. – 2:30 p.m.
- Breakout Sessions: Identifying Roadblocks and Priorities
- Group 1: Molecular/Cellular/Physiological Mechanisms of BPH and LUTS; Development of a Conceptual Model/Approach to Molecular Endophenotypes
- Group 2: Translational Approaches; Identifying New Therapeutic Targets
- Group 3: Needed Methods and Tools
- Group 4: Clinical Research Needs and Approaches (Includes Health Services and EPI and Health Disparities)
- 2:30 p.m. – 2:45 p.m.
- Session Change
- 2:45 p.m. – 3:45 p.m.
- Final Breakout Session Reports and Group Discussion
- 3:45 p.m. – 4:00 p.m.
- Closing Remarks
- 4:00 p.m.
- Adjournment
Abstracts
Abstracts
Popovics (PDF, 18.13 KB)
Roldán-Alzate (PDF, 16.43 KB)
Sarma (PDF, 15.34 KB)
Tripathi (PDF, 17.57 KB)
Vickman (PDF, 45.06 KB)
Submitting Abstracts
All abstracts must be submitted via email to Mark Dennis (mdennis@scgcorp.com), with “Abstract-Male LUTS/BPH Workshop” in the subject line. The abstract submission should be a 1-page Microsoft Word document that does not exceed 250 words (not including the abstract’s title and name and affiliation of all authors).
Presenters are welcome to present abstracts previously-presented in other venues.
Download the Abstract Template (DOCX, 24.67 KB) .
Abstract Organization
Organize the body of the abstract as follows:
- Statement of the study’s purpose
- Statement of the methods used
- Summary of the results presented in sufficient detail to support the conclusion
- Statement of the conclusions reached
Formatting Requirements
Please follow the instructions below to format an abstract. (Note: Submissions will not be edited for spelling or grammar and will be accepted “as is.”)
- The abstract should be a Microsoft Word document with 1-inch margins, typed single space, using Times New Roman font; a 12-point font should be used for everything except the title.
- The abstract’s title should be Typed in Title Case using Bold 16-Point font, and it should clearly represent the nature of the investigation. Do not use subheadings (e.g., Methods, Results) in the body of the abstract.
- Skip one line after the title, and list the author’s first and last names, degree, affiliation, city, state, and country. Separate multiple authors with a semicolon, and underline the primary author’s name (one primary author per abstract).
- Use one blank line between the title and the authors, the authors and the body of the abstract, and between paragraphs.
- Please ensure that your abstract is the correct length (no longer than 250 words).
- Use standard abbreviations (e.g., RBC) and standard symbols for units of measure (e.g., kg, g, mg, mL, L, and %). Place abbreviations and acronyms in parentheses after the full word the first time that the term appears. Use numerals to indicate numbers, except as the first word of a sentence.
- Simple tables or graphs may be included; however, the abstract may not be longer than one page, including any tables or graphs.
Poster Presentations
Posters will be presented as both a virtual poster and a short oral abstract during the poster session. Please record a 5-minute presentation of your abstract and send the .mp4 file to XXX. Come prepared to present your poster as an ePoster during the 1:1 session. ePosters can be a single page (like a traditional poster you would bring to an in-person meeting) OR a multi-slide presentation (no more than 5 total slides, excluding the first slide for Title).
